SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on Capricors 24-month HOPE-3 open-label extension data presented at the World Muscle Society congress; traders are highlighting delayed-start results they view as evidence that deramiocel slows upper-limb decline. Bulls see the data as support for the pending FDA review, while others question how much open-label results can resolve the agencys concerns about the trials statistical analysis.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal fourth-quarter report is driving attention, with traders focused on whether tight DRAM and NAND supply, HBM demand and pricing can support a strong outlook. Many expect a beat and continued AI-driven demand, while others warn that high expectations and the memory markets cyclical nature could prompt a sell-the-news reaction or renewed doubts about how long the boom can last.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeings 737 MAX software glitch and the FAAs resulting delay to MAX 10 certification are driving discussion, with traders debating whether the issue is a manageable fix or another setback to certification, deliveries, and confidence in Boeing. Many bullish traders call the selloff excessive, while others remain wary of the companys recurring quality and execution problems.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desks prolonged selloff and fresh multiyear lows are fueling concern over slowing growth, weak advertising demand, and competition from Amazon and other platforms. Traders debate whether the decline reflects a damaged business or an oversold opportunity, while many criticize management and point to the companys cash position as a reason for optimism.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods summit and product updatesespecially planned 24/7 stock trading, longer options hours, and agentic trading toolsare drawing attention, alongside September trading-volume figures and analyst upgrades. Traders are enthusiastic about the platform expansion but frustrated that the stock has struggled to hold rallies and break resistance.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Uncertainty over federal cannabis rescheduling is driving attention, especially a procedural pause in the DEA hearing after opponents sought to add a GAO report on gaps in drug-scheduling procedures, delaying the expected administrative law judge recommendation. Traders disagree on the impact: some fear the delay could prolong or threaten Schedule III reform, while others view it as a temporary procedural issue and a buying opportunity.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, reflecting stronger demand for its cancer therapies, is driving a sharp rally and renewed analyst optimism. Traders are also focused on future pipeline data, while debating whether short covering is amplifying the move and whether profit-taking or dilution could weigh on shares.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs move to include VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing, together with Rocket Mortgages plan to prefer VantageScore for eligible loans, has triggered a sharp selloff as traders reassess FICOs mortgage-market share and pricing power. The debate is whether competition materially weakens FICOs moat or whether the decline overstates the threat given its established role; some traders are looking for a rebound while others expect further pressure.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieves addition to the S&P Total Market and S&P Completion indices drew attention, with traders welcoming the inclusion and discussing potential index-related buying. The broader conversation remains focused on federal cannabis rescheduling: some see the pending Schedule III process as a tailwind, while others are frustrated by delays and uncertainty around the judges recommendation.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths SPAC merger and Nasdaq transition are the main focus, alongside its planned XRP treasury of roughly 473 million tokens. Traders are treating XRPN as an equity proxy for XRP and debating the mergers timing, potential share backing and warrant leverage, while noting sharp moves and trading halts; views on the risk and valuation differ.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Stocks are Refusing to Cool Off

The closing bell is shaping up to be anything but quiet for these names that stand out as the session heads toward the finish. Greenland Energy Company (NASDAQ:GLND), NeOnc Technologies Holdings (NASDAQ:NTHI), GRAIL (NASDAQ:GRAL), Warby Parker (NYSE:WRBY), Montauk Renewables (NASDAQ:MNTK), Ginkgo Bioworks Holdings (NYSE:DNA), and CareDx (NASDAQ:CDNA).

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.

Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to...

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Healths (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime...

Ginkgo Bioworks Holdings Enters Oversold Territory (DNA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think

Palantir (NASDAQ: PLTR) and Ginkgo Bioworks (NYSE: DNA) sit on opposite sides of a fast-emerging biosecurity debate. Palantir represents the intelligence layer, while Ginkgo represents the biological infrastructure layer. The question is whether future value comes from identifyin...

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings...

The $59B Quiet Shift Reshaping How Patients Access Care

The $59B Quiet Shift Reshaping How Patients Access Care The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026 Issued on behalf of VentriPoint Diagnostics...

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$11.96
Prev Close	$10.46
Open	$10.54
Dividend Yield	0.00%
50-Day Moving Average	$7.71
Beta	2.62
Avg. Volume	1.28M
PE Ratio	-1.92

52-Week High	$17.58
52-Week Low	$5.37
Market Capitalization	$704.38M
EPS (Annual)	-$5.64
Price to Book	1.51
Revenue Per Employee	$350,835.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNA Fundamentals